Review Article

Prostaglandins and Rheumatoid Arthritis

Mohammad Javad Fattahi and Abbas Mirshafiey

Department of Immunology, School of Public Health, Tehran University of Medical Sciences, P.O. Box 6446, Tehran 14155, Iran

Correspondence should be addressed to Abbas Mirshafiey, mirshafiey@tums.ac.ir

Received 21 July 2012; Revised 26 September 2012; Accepted 18 October 2012

Academic Editor: Peter M. van der Kraan

Copyright © 2012 M. J. Fattahi and A. Mirshafiey. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Rheumatoid arthritis (RA) is a chronic, autoimmune, and complex inflammatory disease leading to bone and cartilage destruction, whose cause remains obscure. Accumulation of genetic susceptibility, environmental factors, and dysregulated immune responses are necessary for mounting this self-reacting disease. Inflamed joints are infiltrated by a heterogeneous population of cellular and soluble mediators of the immune system, such as T cells, B cells, macrophages, cytokines, and prostaglandins (PGs). Prostaglandins are lipid inflammatory mediators derived from the arachidonic acid by multienzymatic reactions. They both sustain homeostatic mechanisms and mediate pathogenic processes, including the inflammatory reaction. They play both beneficial and harmful roles during inflammation, according to their site of action and the etiology of the inflammatory response. With respect to the role of PGs in inflammation, they can be effective mediators in the pathophysiology of RA. Thus the use of agonists or antagonists of PG receptors may be considered as a new therapeutic protocol in RA. In this paper, we try to elucidate the role of PGs in the immunopathology of RA.

1. Introduction

Rheumatoid arthritis (RA) is a complex autoimmune and progressive inflammatory disease that involves the joints and leads to their destruction. The prevalence of rheumatoid arthritis (RA) is 0.5%–1.0% in the general population worldwide [1, 2]. Females are nearly three times more likely than males to develop the disease and can start at any age, although the mean age at the onset is 40 to 60 years [3, 4]. The precise cause of rheumatoid arthritis is unknown; like other autoimmune diseases it arises from a variable combination of genetic susceptibility, environmental factors, and the inappropriate activation of the immune responses that eventually result in the clinical signs of arthritis [5]. Multiple genes are associated with disease susceptibility, with the HLA locus accounting for 30% to 50% of the overall genetic risk. Several risk loci have been recognized: HLA-DRB1, PTPN22, STAT4, CTLA4, RAD14 a region in 6q23, and the TRAF1/C5 locus [6–9]. Similarly, the mouse strains of DBA/1 and B10.Q have the I-Aq and I-Ar haplotypes and are highly susceptible to collagen-induced arthritis (CIA), as experimental models of RA [10, 11]. The important role of HLA-DR antigens is to present antigens to T lymphocytes, whereas the PTPN22 protein tyrosine phosphatase appears to have a potential function in the setting of T-cell and B-cell activation [12]. Smoking, the best-known environmental factor, in certain genetic context of HLA-DRB1 can trigger immunity to citrulline-modified proteins and this response, after several years, causes arthritis [13, 14]. The adaptive and innate immune responses in the synovial fluid are involved in the pathogenesis of RA. High levels of autoantibodies, including rheumatoid factors and anticitrullinated peptide antibodies, can be diagnosed before the onset of clinical arthritis [15]. Inflamed joint tissues are infiltrated by monocyte/macrophage, rheumatoid arthritis synovial fibroblast (RASF), T cells, and B cells. These cells release proinflammatory cytokines such as interleukin 1(IL-1), IL-17, and tumor necrosis factor α(TNF-α), that
play important roles in progressive joint destruction and are closely associated with the production of small proinflammatory lipid mediators such as prostaglandins [16, 17].

2. Prostaglandins

Prostaglandins are small potent inflammatory mediators that are generated by the release of arachidonic acid (AA) from the membrane phospholipids by the phospholipase A2 (plpA2) family. Subsequently, cyclooxygenase (COX; prostaglandin endoperoxide H synthase; PGHS) and Prostaglandin synthase enzymes metabolize AA to prostaglandins including PGE$_2$, PGF$_{2\alpha}$, PGD$_2$, PGI$_2$ (prostacyclin), and TXA$_2$(thromboxane), that play pivotal roles in the modulation of physiological systems, such as CNS, and the inflammatory and immune responses [18, 19]. The cyclooxygenases are heme containing enzymes that have two major isoforms in mammals named COX-1 and COX-2. Although COX-1 and COX-2 have about 60% homology at the amino acid level and catalyze the same reactions, they have different patterns of expression and are encoded by different genes [20, 21]. COX-1 is constitutively expressed in many tissues and is responsible for the physiological function of PGs and thus is known as a “housekeeping” enzyme whereas COX-2 expression is induced by inflammatory mediators like cytokines, growth factors, and bacterial endotoxins [21, 22]. Traditional NSAIDs (non-steroidal anti-inflammatory drugs), that have antipyretic, analgesic, and anti-inflammatory properties, inhibit both COX isozymes. The recently developed COX-2-selective inhibitors retain effectiveness in reducing inflammation and pain in rheumatoid and osteoarthritis but have a lower incidence of gastrointestinal side effects [23]. Prostaglandins use G-protein coupled receptors (GPCRs) for exerting their functions. The prostaglandins receptors subfamilies include DP, EP1-4, FP, IP, and TP which bind to PGD$_2$, PGE$_2$, PGF$_{2\alpha}$, PGI$_2$, and TXA$_2$, respectively [24]. Recently, another PGD$_2$ receptor, the chemoattractant receptor homologous molecule expressed on Th2 cells (CRTH2), was identified [25]. The prostaglandins (PGs) found at elevated levels in the synovial fluid and the synovial membrane are considered to play a pivotal role in the development of vasodilatation, fluid extravasation, and pain in synovial tissues. Moreover, there is an increasing evidence that PGs (especially prostaglandin E$_2$) are mediators involved in complex interactions leading to the development of erosions of the articular cartilage and the juxta-articular bone [26]. PG synthesis inhibitors (COX-2 inhibitors and NSAIDs) are widely used in the treatment of RA [27].

3. Prostaglandins and Rheumatoid Arthritis

3.1. PGD$_2$ and RA. Prostaglandin D synthase is responsible for the generation of the PGD$_2$ and J series. This enzyme has two isoforms including the lipocalin (brain) type PGDS (L-PGDS) which is responsible for PGD$_2$ biosynthesis in the CNS where it plays a central role in the regulation of sleep and the hematopoietic PGDS (h-PGDS) which is also known as “spleen type” PGD$_2$ synthase [28, 29]. PGD$_2$ regulates multiple physiologic and pathologic processes, such as sleep, nociception, vasodilation, bronchoconstriction, and bone metabolism. PGD$_2$ has anti-inflammatory effects in several models of inflammation [30, 31]. It exerts its function by binding two receptors, DP1 and CRTH2. DP1 activation by PGD$_2$ causes the elevation of intracellular cAMP level which is typically associated with damping of the cellular effector function, whereas the CRTH2/DP2 receptor stimulation leads to the elevation of intracellular Ca$^{2+}$. DP2 activation by PGD$_2$ induces TH2 cytokines production, their migration, and enhancing their adhesiveness to endothelial surfaces [29]. On the other hand, when PGD$_2$ is produced in a large amount for activating PPAR-$\gamma$, it will be able to inhibit T-lymphocyte proliferation and, consequently, the inflammatory response. In contrast, if only nanomolar concentrations of PGD$_2$ and its metabolites are produced, the PGs may be expected to activate T lymphocytes [25, 32, 33]. In synovial fluid, PGD$_2$ abundantly is released by chondrocytes [33], osteoclasts [34], synovial fibroblast, and mast cells [35, 36]. It inhibits chondrocyte apoptosis [37], stimulates chondrogenic differentiation, enhances the expression of collagen type II and aggrecan [38], prevents IL-1-induced generation of MMP-1 (metalloproteinase-1) and MMP-13 by chondrocytes through the DP1/cAMP/PKA signaling pathway, indicating that PGD$_2$ may contribute to the cartilage maintenance and integrity [39, 40]. PGD$_2$ is readily dehydrated and generates PGs of the J series, such as PGJ$_2$, $\delta$-12-PGJ$_2$, and $\delta$-15-deoxy-$\delta$12,14-PGJ$_2$ (15d-PGJ$_2$). The 15d-PGJ$_2$ was identified as a ligand for peroxisome proliferator activated receptor-$\gamma$ (PPAR-$\gamma$) which enhances the differentiation of adipocytes and trophoblasts [41, 42] and implicates as a mediator of many anti-inflammatory effects of PGD$_2$ [43]. 15d-PGJ$_2$ is released by articular chondrocytes and diagnosed in synovial fluid RA patients. It enhances chondrocyte apoptosis in a dose- and time-dependent manner by a PPAR-$\gamma$-dependent pathway [44]. PGD$_2$ and its metabolite, 15d-PGJ$_2$, may have chondroprotective effects. For instance, they counteract the induction of matrix metalloproteinases in cytokine-activated chondrocytes, which play an important role in cartilage degradation [39, 45]. The 15d-PGJ$_2$ inhibits the production of several inflammatory mediators by monocytes/macrophages. It blocks nitric oxide (NO) production as well as proteoglycan degradation [45–48]. 15d-PGJ$_2$ also inhibits apoptosis of human primary chondrocytes induced by the NF-$\kappa$B inhibitor (Bay 11–7085) [37, 49].

3.2. PGE$_2$ and RA. PGE$_2$ is the major PG that is generated by chondrocytes and synovial fibroblasts; the biosynthesis can be enhanced by proinflammatory cytokines such as IL-1$\beta$, TNF-$\alpha$, and trauma [50]. Prostaglandin E synthase (PGES) converts COX-derived PGH$_2$ to PGE$_2$ [51], a potent lipid mediator, that regulates a broad range of physiological activities in the immune and the other biological systems such as cardiovascular, endocrine, gastrointestinal, neural,
pulmonary, reproductive, and visual systems [52]. Three different forms of the PGEs have been identified, microsomal PGES-1,2 (mPGES-1,2) and cytosolic PGES(cPGES, p23). mPGES-1 is preferentially linked with COX-2 and is induced in response to various stimuli [53]. Glutathione-independent mPGES-2 is a unique PGE that is constitutively expressed and coupled with both COXs in the production of the PGE_2 involved in both tissue homeostasis and disease [30, 54]. The cPGES is constitutively expressed and to be preferentially coupled to COX-1 than COX-2 and its expression is not affected by proinflammatory stimuli [55]. Of the three PGES isozymes, mPGES-1 is upregulated in synovial fluid in active RA and is minimally expressed in inactive RA [56]. The mPGES-1 induction is coordinated with COX-2 expression under inflammatory conditions in different cells and tissues as well as RA synovium. Some of selective COX-2 inhibitors may cause cardiovascular side effects in RA patients due to simultaneous decrease in production of PGE2 and antithrombotic PGII2. In order to reduce this side effect selective inhibition of mPGES-1 derived PGE2 production will be an desirable therapeutic alternative [57, 58]. PGE_2 exerts its diverse roles by acting on a group of rhodopsin-like 7-transmembrane-spanning GPCRs: EP1, EP2, EP3, and EP4. The EP subtypes show differences in binding affinity, signal transduction, tissue localization, and regulation of expression. The EP3 and EP4 are the most abundant of the EP receptors and their binding affinity to PGE2 is higher than EP1 and EP2 receptors [59, 60]. EP receptors link to different intracellular signaling molecules that mediate the effects of receptor activation on cell function. EP2 and EP4 receptors couple to a Gs-type G-protein that activate adenylyl cyclase, increasing intracellular cAMP. EP1 links to Gq and activates phosphatidylinositol metabolism leading to mobilization of intracellular free calcium. EP3 receptor can couple to Gi or G12 for elevation of intracellular Ca2+, activation of phosphatidylinositol metabolism leading to an increase in the production of the PGE2-EP4 signaling in OA cartilage. PGE2-EP4 induces matrix metalloproteinase production and type II collagen degradation. PGE2 through EP4 receptor shows a potent antianabolic effect on human adult articular cartilage in vitro via the suppression of proteoglycan biosynthesis, which suggests EP4 receptor antagonist could be as a potential therapeutic agent for the treatment of osteoarthritis and RA [72, 73]. Clark et al. also found that a selective EP4 antagonist reduces COX-2-dependent arthritic inflammation and pain (NSAID-like activity). This reagent is well tolerated by the gastrointestinal tract and, unlike COX-2 inhibitors, it does not inhibit PGI2 and may be cardioprotective [74]. PGE2 has also inhibitory effects on NF-kB through ERK-dependent and -independent pathways in RASF, key mediators of RA inflammation, and cartilage erosion. This process may paradoxically inhibit the action of inflammatory cytokines and may participate in the resolution phase of inflammation to prevent cartilage degradation in arthritis [75].

3.3. PG12 and RA. Prostacyclin (PGI2) the main PG produced by vascular endothelial cells exerts its functions through a seven-transmembrane-spanning GPCR, known as the IP receptor. Both cyclooxygenase enzymes (COX-1/2) convert AA into the prostaglandin precursor PGH2, which is subsequently converted into PGI2 via prostacyclin synthase (PGIS), a member of cytochrome P450 superfamily [76, 77]. The IP receptor is coupled predominately to a Gs subunit (and in some circumstances with Gi- and Gq-dependent pathways) and the G-protein leads to an increase in the cAMP level and this signaling pathway is responsible for vasodilatory and antithrombotic effects of prostacyclin [78–80]. PGI2 may also signal through the PPAR-γ pathway [81]. Prostacyclin plays a regulatory role within the cardiovascular system. It has been found that the IP receptor signaling by enhancing Th2-cell production of the anti-inflammatory cytokine IL-10 inhibits Th2-mediated allergic inflammatory responses [19, 82]. PGI2 is the most frequent prostaglandin in synovial fluid of patients with RA [83]. In rheumatoid
arthritic PG\(_2\) acts as a proinflammatory lipid mediator. IP receptor antagonists inhibit experimental hyperalgesia, edema, and osteoarthritis in the rat, indicating that prostacyclin plays an important role in these pathological conditions. In CIA, IP receptor-deficient mice showed a significant decrease in arthritic score in spite of anticollegen antibodies and complement activation similar to wild-type mice. In addition, the administration of the IP antagonist in this model also reduced the symptoms (NSAID-like efficacy) [84, 85].

3.4. PGF\(_{2\alpha}\) and RA. Prostaglandin F\(_{2\alpha}\)(PGF\(_{2\alpha}\)) is biosynthesized from PGH\(_2\) and other PGs (PGE\(_2\), PGD\(_2\)) by three enzymes, PGH\(_9\)-, 11-endoperoxide reductase, PGE\(_9\)-ketoreductase, and PGD\(_{11}\)-ketoreductase, respectively [86]. It exerts its biological functions by binding to a prostanoid receptor FP which has two differentially spliced variants (FP\(_A\), FP\(_B\)). The FP receptor couples with the G\(_4\) protein for increasing the inositol phosphate accumulation, protein kinase C (PKC) activation, and intracellular calcium release [87]. In addition, stimulation of FP receptor leads to activation of G-protein Rho via a Gq-independent process, resulting in cytoskeleton rearrangement [88]. The FP receptor is the least selective of the prostaglandin receptors in binding the principal endogenous prostaglandins, binding both PGD\(_2\) and PGE\(_2\) at nanomolar concentrations [19]. PGF\(_{2\alpha}\) has a pivotal role in the reproductive system, renal function, contraction of arteries, myocardial dysfunction, and regulation of intraocular pressure and pain [89–93]. Basu showed that the oxidative metabolism of arachidonic acid through both enzymatic (cyclooxygenase) and nonenzymatic (free radical) pathways is engaged in endotoxin-induced inflammation in pigs as indicated by the significantly increased formation of F\(_2\)-isoprostane and PGF\(_{2\alpha}\) metabolite in plasma [94]. They also showed that the measurement of F\(_2\)-isoprostanes in body fluids provides a reliable analytical tool to study oxidative stress-related diseases and experimental inflammatory conditions [95]. High levels of both free radical mediated F\(_2\)-isoprostanes and the cyclooxygenase derived PGF\(_{2\alpha}\) metabolite were diagnosed in blood and synovial fluid from patients with various rheumatic diseases such as RA and OA that shows both oxidative injury and inflammation play a role in various degrees in chronic inflammatory conditions [96]. The arising role of PGF\(_{2\alpha}\) in inflammatory reactions opens the unique opportunities for designing the new anti-inflammatory drugs [61].

4. Conclusion

Elevated levels of prostaglandins have been diagnosed in the synovial fluid and synovial membrane of RA patients. In the inflamed joints PGs play pivotal roles through complex interactions with leukocytes and other cells. They can induce both pro- and anti-inflammatory responses, depending on the receptor subtype, cell population, context of activation, and the receptor gene expression in tissues. The role of prostaglandins in the metabolism of articular cartilage is still controversial. Some studies show that prostaglandins contribute to the destruction of articular cartilage by degrading cartilage ECM, while others found that they induce chondrogenesis and terminal differentiation. The different biological roles attributed to these lipid mediators are a direct indication of the molecular complexity of prostaglandins and their exclusive cognate receptors. Mice deficient in individual PGs receptors and combinations of these receptors will allow the investigation of the role of these receptors and their ligands in various models of inflammatory diseases such as RA. The most important therapies for RA should both inhibit inflammation and activate resolution. A broad spectrum of different enzyme inhibitors and receptor antagonists has been studied, showing a variety of effects on the course of the disease. Thus, it seems that the pharmacological intervention to modulate the release of lipid mediators will be important to improve the patient outcomes. The research efforts of recent years, however, contribute to a better understanding of the pathophysiological impact of lipid mediators in inflammatory disorders and provide new therapeutic approaches.

References

[1] R. C. Lawrence, C. G. Helmick, F. C. Arnett et al., "Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States," *Arthritis & Rheumatism*, vol. 41, no. 5, pp. 776–799, 1998.
[2] A. J. Silman and J. E. Pearson, "Epidemiology and genetics of rheumatoid arthritis," *Arthritis Research*, vol. 4, supplement 3, pp. S265–S272, 2002.
[3] J. S. Smolen and G. Steiner, "Therapeutic strategies for rheumatoid arthritis," *Nature Reviews Drug Discovery*, vol. 2, no. 6, pp. 473–488, 2003.
[4] J. R. O’Dell, J. S. Smolen, D. Aletaha, D. R. Robinson, and E. W. Saint Clair, "Rheumatoid arthritis," in *A Clinician’s Pearls and Myths in Rheumatology*, J. H. Stone, Ed., pp. 1–13, Springer, London, UK, 2010.
[5] L. C. Huber, O. Distler, I. Turner, R. E. Gay, S. Gay, and T. Pap, "Synovial fibroblasts: key players in rheumatoid arthritis," *Rheumatology*, vol. 45, no. 6, pp. 669–675, 2006.
[6] J. B. Imboden, "The immunopathogenesis of rheumatoid arthritis," *Annual Review of Pathology*, vol. 4, pp. 417–434, 2009.
[7] R. De Vries, "Genetics of rheumatoid arthritis: time for a changel!," *Current Opinion in Rheumatology*, vol. 23, no. 3, pp. 227–232, 2011.
[8] S. Eyre, A. Barton, N. Shephard et al., "Investigation of susceptibility loci identified in the UK rheumatoid arthritis whole-genome scan in a further series of 217 UK affected sibling pairs," *Arthritis and Rheumatism*, vol. 50, no. 3, pp. 729–735, 2004.
[9] D. Jawaheer, M. F. Seldin, C. I. Amos et al., "Screening the genome for rheumatoid arthritis susceptibility genes: a replication study and combined analysis of 512 multicase families," *Arthritis and Rheumatism*, vol. 48, no. 4, pp. 906–916, 2003.
[10] A. Doncarli, G. Chiocchia, L. M. Stasiuk et al., "A recurrent valpha17/vbeta10 TCR-expressing T cell clone is involved in the pathogenicity of collagen-induced arthritis in DBA/1
mice,” *European Journal of Immunology*, vol. 29, no. 11, pp. 3636–3642, 1999.

[11] G. E. Osman, M. Toda, O. Kanagawa, and L. E. Hood, “Characterization of the T cell receptor repertoire causing collagen arthritis in mice,” *Journal of Experimental Medicine*, vol. 177, no. 2, pp. 387–395, 1993.

[12] H. Källberg, L. Padyukov, R. M. Plenge et al., “Gene-gene and gene-environment interactions involving HLA-DRB1, PTPN22, and smoking in two subsets of rheumatoid arthritis,” *American Journal of Human Genetics*, vol. 80, no. 5, pp. 867–875, 2007.

[13] L. Klareskog, L. Padyukov, J. Lorentzen, and L. Alfredsson, “Role of genetic susceptibility and environmental triggers in the development of rheumatoid arthritis,” *Nature Clinical Practice Rheumatology*, vol. 2, no. 8, pp. 425–433, 2006.

[14] G. J. Tobón, P. Youinou, and A. Saraux, “The environment, geo-epidemiology, and autoimmune disease: rheumatoid arthritis,” *Autoimmunity Reviews*, vol. 9, no. 5, pp. A288–A292, 2010.

[15] M. J. Nielsen, D. Van Schaardenburg, H. W. Reesink et al., “Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors,” *Arthritis and Rheumatism*, vol. 50, no. 2, pp. 380–386, 2004.

[16] M. Kuligowska and G. Odrowąż-Sypniewska, “Role of interleukin-17 in cartilage and bone destruction in rheumatoid arthritis,” *Ortopedia, Traumatologia, Rehabilitacja*, vol. 6, no. 2, pp. 235–241, 2004.

[17] J. Zwerina, K. Redlich, G. Schett, and J. S. Smolen, “Pathogenesis of rheumatoid arthritis: targeting cytokines,” *Annals of the New York Academy of Sciences*, vol. 1051, pp. 716–729, 2005.

[18] T. Shimizu, “Lipid mediators in health and disease: enzymes and receptors as therapeutic targets for the regulation of immunity and inflammation,” *Annual Review of Pharmacology and Toxicology*, vol. 49, pp. 123–150, 2009.

[19] A. N. Hata and R. M. Breyer. "Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation," *Pharmacology and Therapeutics*, vol. 103, no. 2, pp. 147–166, 2004.

[20] D. Milatovic, T. J. Montine, and M. Aschner, "Prostanoid signaling: dual role for prostaglandin E2 in neurotoxicity," *NeuroToxicology*, vol. 32, no. 3, pp. 312–319, 2011.

[21] C. A. Rouzer and L. J. Marnett, "Cyclooxygenases: structural and functional insights," *Journal of Lipid Research*, vol. 50, pp. S29–S34, 2009.

[22] S. Hayashi, N. Ueno, A. Murase, Y. Nakagawa, and J. Takada, “Novel acid-type cyclooxygenase-2 inhibitors: design, synthesis, and structure-activity relationship for anti-inflammatory drug,” *European Journal of Medicinal Chemistry*, vol. 50, pp. 179–195, 2012.

[23] G. A. FitzGerald and C. Patrono, “The coxibs, selective inhibitors of cyclooxygenase-2,” *The New England Journal of Medicine*, vol. 345, no. 6, pp. 433–442, 2001.

[24] R. M. Breyer, C. K. Bagdassarian, S. A. Myers, and M. D. Breyer, “Prostanoid receptors: subtypes and signaling,” *Annual Review of Pharmacology and Toxicology*, vol. 41, pp. 661–690, 2001.

[25] H. Hirai, K. Tanaka, O. Yoshie et al., “Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2,” *Journal of Experimental Medicine*, vol. 193, no. 2, pp. 255–261, 2001.

[26] L. J. Crofford, R. L. Wilder, A. P. Ristimaki et al., “Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. Effects of interleukin-1β, phorbol ester, and corticosteroids,” *Journal of Clinical Investigation*, vol. 93, no. 3, pp. 1095–1101, 1994.

[27] A. M. Pulchino, S. Rowland, T. Wu et al., “Prostacyclin antagonism reduces pain and inflammation in rodent models of hyperalgesia and chronic arthritis,” *Journal of Pharmacology and Experimental Therapeutics*, vol. 319, no. 3, pp. 1043–1050, 2006.

[28] S. Saito, H. Tsuda, and T. Michimata, “Prostaglandin D2 and reproduction,” *American Journal of Reproductive Immunology*, vol. 47, no. 5, pp. 295–302, 2002.

[29] S. P. Khanapure, D. S. Garvey, D. R. Janero, and L. G. Letts, “Eicosanoids in inflammation: biosynthesis, pharmacology, and therapeutic frontiers,” *Current Topics in Medicinal Chemistry*, vol. 7, no. 3, pp. 311–340, 2007.

[30] M. Murakami, K. Nakashima, D. Kamei et al., “Cytokines and prostaglandin E2 production by membrane-bound prostaglandin E synthase-2 via both cyclooxygenases-1 and -2,” *The Journal of Biological Chemistry*, vol. 278, no. 39, pp. 37937–37947, 2003.

[31] D. W. Gilroy, P. R. Colville-Nash, D. Willis, J. Chivers, M. J. Paul-Clark, and D. A. Willoughby, “Inducible cyclooxygenase may have anti-inflammatory properties,” *Nature Medicine*, vol. 5, no. 6, pp. 698–701, 1999.

[32] K. Tanaka, H. Hirai, S. Takano, M. Nakamura, and K. Nagata, “Effects of prostaglandin D2 on helper T cell functions,” *Biochemical and Biophysical Research Communications*, vol. 316, no. 4, pp. 1009–1014, 2004.

[33] D. Egg, “Concentration of prostaglandins D2, E2, F(2α), 6-keto-F(1α) and thromboxane B2 in synovial fluid from patients with inflammatory joint disorders and osteoarthritis,” *Zeitschrift fur Rheumatologie*, vol. 43, no. 2, pp. 89–96, 1984.

[34] M. A. Gallant, R. Samadfam, J. A. Hackett, J. Antoniou, B. Relić, V. Benoit, N. Franchimont et al., “15-Deoxy-Delta12,14-prostaglandin J2 inhibits bone 11-7085-induced sustained extracellular signal-regulated kinase phosphorylation and apoptosis in human articular chondrocytes and synovial fibroblasts,” *The Journal of Biological Chemistry*, vol. 279, no. 21, pp. 22399–22403, 2004.

[35] M. Jakob, O. Démarteau, R. Sutterlin, M. Heberer, and I. Martin, “Chondrogenesis of expanded adult human articular chondrocytes is enhanced by specific prostaglandins,” *Rheumatology*, vol. 43, no. 7, pp. 852–857, 2004.

[36] N. Zayed, H. Afif, N. Chabane et al., “Inhibition of interleukin-1β-induced matrix metalloproteinases 1 and 3 production in human osteoarthritic chondrocytes by prostaglandin D 2,”
Arthritis and Rheumatism, vol. 58, no. 11, pp. 3530–3540, 2008.

[40] N. Zayed, X. Li, N. Chabane et al., “Increased expression of lipocalin-type prostaglandin D2 synthase in osteoarthritic cartilage,” Arthritis Research and Therapy, vol. 10, no. 6, article no. R146, 2008.

[41] W. T. Schaiff, M. G. Carlson, S. D. Smith, R. Levy, D. M. Nelson, and Y. Sadovsky, “Peroxisome proliferator-activated receptor-γ modulates differentiation of human trophoblast in a ligand-specific manner,” Journal of Clinical Endocrinology and Metabolism, vol. 85, no. 10, pp. 3874–3881, 2000.

[42] B. M. Forman, P. Tontonoz, J. Chen, R. P. Brun, B. M. Spiegelman, and R. M. Evans, “15-deoxy-Δ12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ,” Cell, vol. 85, no. 5, pp. 803–812, 1995.

[43] S. G. Trivedi, J. Newson, R. Rajakariar et al., “Essential role for hematopoietic prostaglandin D2 synthase in the control of delayed type hypersensitivity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 13, pp. 5179–5184, 2006.

[44] Z. Z. Shan, K. Masuko-Hongo, S. M. Dai, H. Nakamura, T. Kato, and K. Nishioka, “A potential role of 15-deoxy-Δ12,14-prostaglandin J2 for induction of human articular chondrocyte apoptosis in arthritis,” The Journal of Biological Chemistry, vol. 279, no. 36, pp. 37939–37950, 2004.

[45] H. Fahmi, J. A. Di Battista, J. P. Pelletier, F. Mineau, P. Ranger, and J. Martel-Pelletier, “Peroxisome proliferator—activated receptor gamma activators inhibit interleukin-1β-induced nitric oxide and matrix metalloproteinase 13 production in human chondrocytes,” Arthritis & Rheumatism, vol. 44, no. 3, pp. 595–607, 2001.

[46] M. Ricote, A. C. Li, T. M. Willson, C. J. Kelly, and C. K. Glass, “The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation,” Nature, vol. 391, no. 6662, pp. 79–82, 1998.

[47] C. J. Jiang, A. T. Ting, and B. Seed, “PPAR-γ agonists inhibit production of monocye inflammatory cytokines,” Nature, vol. 391, no. 6662, pp. 82–86, 1998.

[48] K. Bordji, J. P. Grillasca, J. N. Gouze et al., “Evidence for the presence of peroxisome proliferator-activated receptor (PPAR) α and γ and retinoid Z receptor in cartilage. PPARγ activation modulates the effects of interleukin-β on rat chondrocytes,” The Journal of Biological Chemistry, vol. 275, no. 16, pp. 12243–12250, 2000.

[49] F. Zhu, P. Wang, A. Kontogianni-Konstantopoulou, and K. Konstantopoulou, “Prostaglandin (PG)D(2) and 15-deoxy-Delta(12,14)-PG(2), but not PGE(2), mediate shear-induced chondrocyte apoptosis via protein kinase A-dependent regulation of polo-like kinases,” Cell Death and Differentiation, vol. 17, no. 8, pp. 1325–1334, 2010.

[50] J. Martel-Pelletier, J. P. Pelletier, and H. Fahmi, “Cyclooxygenase-2 and prostaglandins in articular tissues,” Seminars in Arthritis and Rheumatism, vol. 33, no. 3, pp. 155–167, 2003.

[51] D. Claveau, M. Sirinyan, J. Guay et al., “Microsomal prostaglandin E synthase-1 is a major terminal synthase that is selectively up-regulated during cyclooxygenase-2-dependent prostaglandin E2 production in the rat adjuvant-induced arthritis model,” Journal of Immunology, vol. 170, no. 9, pp. 4738–4744, 2003.

[52] J. Akaogi, T. Nozaki, M. Satoh, and H. Yamada, “Role of PGE2 and EP receptors in the pathogenesis of rheumatoid arthritis and as a novel therapeutic strategy,” Endocrine, Metabol and Immune Disorders - Drug Targets, vol. 6, no. 4, pp. 383–394, 2006.

[53] K. Gudis and C. Sakamoto, “The role of cyclooxygenase in gastric mucosal protection,” Digestive Diseases and Sciences, vol. 50, supplement 1, pp. S16–S23, 2005.

[54] N. Tanioka, Y. Ohmiya, H. Ohkubo et al., “Identification and characterization of a novel type of membrane-associated prostaglandin E synthase,” Biochemical and Biophysical Research Communications, vol. 291, no. 4, pp. 884–889, 2002.

[55] T. Tanioka, Y. Nakatani, N. Semmyo, M. Murakami, and I. Kudo, “Molecular identification of cytosolic prostaglandin E2 synthase that is functionally coupled with cyclooxygenase-1 in immediate prostaglandin E2 biosynthesis,” The Journal of Biological Chemistry, vol. 275, no. 42, pp. 32773–32782, 2000.

[56] H. Sano, “The role of lipid mediators in the pathogenesis of rheumatoid arthritis,” Inflammation and Regeneration, vol. 31, no. 2, pp. 151–156, 2011.

[57] C. Bombardier, L. Laine, A. Reicin et al., “Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis,” The New England Journal of Medicine, vol. 343, no. 21, pp. 1520–1528, 2000.
[67] A. Haddad, G. Flint-Ashtamker, W. Minzel, R. Sood, G. Rimon, and L. Barki-Harrington, “Prostaglandin EP1 receptor down regulates expression of cyclooxygenase-2 by facilitating its proteasomal degradation,” The Journal of Biological Chemistry, vol. 287, no. 21, pp. 17214–17223, 2012.

[68] M. Miwa, R. Saura, S. Hirata, Y. Hayashi, K. Mizuno, and H. Itoh, “Induction of apoptosis in bovine articular chondrocyte by prostaglandin E2 through cAMP-dependent pathway,” Osteoarthritis and Cartilage, vol. 8, no. 1, pp. 17–24, 2000.

[69] F. Pica, O. Franzese, C. D’Onofrio, E. Bonmassar, C. Favalli, and E. Garaci, “Prostaglandin E2 induces apoptosis in resting immature and mature human lymphocytes: a c-Myc-dependent and Bcl-2-independent associated pathway,” Journal of Pharmacology and Experimental Therapeutics, vol. 277, no. 3, pp. 1793–1800, 1996.

[70] B. O. Porter and T. R. Malek, “Prostaglandin E2 inhibits T cell activation-induced apoptosis and Fas-mediated cellular cytotoxicity by blockade of Fas-ligand induction,” European Journal of Immunology, vol. 29, no. 7, pp. 2360–2365, 1999.

[71] T. Aoyama, B. Liang, T. Okamoto et al., “PGE2 signal through EP2 promotes the growth of articular chondrocytes,” Journal of Bone and Mineral Research, vol. 20, no. 3, pp. 377–389, 2005.

[72] M. Attur, H. E. Al-Mussawir, J. Patel et al., “Prostaglandin E2 exerts catabolic effects in osteoarthritis cartilage: evidence for signaling via the EP4 receptor,” Journal of Immunology, vol. 181, no. 7, pp. 5082–5088, 2008.

[73] S. Otsuka, T. Aoyama, M. Furu et al., “PGE2 signal via EP2 receptors evoked by a selective agonist enhances regeneration of injured articular cartilage,” Osteoarthritis and Cartilage, vol. 17, no. 4, pp. 529–538, 2009.

[74] P. Clark, S. E. Rowland, D. Denis et al., “MF498 [N-4-(5,9-dethoxy-6-oxo-6,8-dihydro-7H-yrrolo[3,4-g]quinolin-7-yl)-3-methylbenzy]sulfonfyl-2-(2-methoxyphenyl)acetamide], a selective E prostaglandin receptor 4 antagonist, relieves joint inflammation and pain in rodent models of rheumatoid and osteoarthritis,” Journal of Pharmacology and Experimental Therapeutics, vol. 325, no. 2, pp. 425–434, 2008.

[75] P. F. Gomez, M. H. Pillinger, M. Attur et al., “Resolution of inflammation: prostaglandin E2 dissociates nuclear trafficking of individual NF-kB subunits (p65, p50) in stimulated rheumatoid synovial fibroblasts,” Journal of Immunology, vol. 175, no. 10, pp. 6924–6930, 2005.

[76] J. Stitham, C. Midgett, K. A. Martin, and J. Hwa, “Prostacyclin: an inflammatory paradox,” Frontiers in Pharmacology, vol. 2, p. 24, 2011.

[77] X. de Leval, J. Hanson, J. L. David, B. Masereel, B. Pirotte, and B. O. Porter, “New developments on thromboxane and prostacyclin modulators part 1: prostacyclin modulators,” Current Medicinal Chemistry, vol. 11, no. 10, pp. 1243–1252, 2004.

[78] Y. Boie, T. H. Rushmore, A. Darmon-Goodvin et al., “Cloning and expression of a cDNA for the human prostaglandin IP receptor,” The Journal of Biological Chemistry, vol. 269, no. 16, pp. 12173–12178, 1994.

[79] Y. Sugimoto, K. Y. Hasumoto, T. Namba et al., “Cloning and expression of a cDNA for mouse prostaglandin F receptor,” The Journal of Biological Chemistry, vol. 269, no. 2, pp. 1356–1360, 1994.

[80] R. L. Hébert, T. O’Connor, C. Neville, K. D. Burns, O. Laniewille, and L. N. Peterson, “Prostanoid signaling, localization, and expression of IP receptors in rat thick ascending limb cells,” American Journal of Physiology, vol. 275, no. 6, pp. F904–F914, 1998.

[81] L. Hyunjung and S. K. Dey, “Mini review: a novel pathway of prostacyclin signaling—hanging out with nuclear receptors,” Endocrinology, vol. 143, no. 9, pp. 3207–3210, 2002.

[82] Z. Jaffar, K. S. Wan, and K. Roberts, “A key role for prostaglandin I2 in limiting lung mucusal Th2, but not Th1, responses to inhaled allergen,” Journal of Immunology, vol. 169, no. 10, pp. 5997–6004, 2002.

[83] M. J. Brodie, C. N. Hensby, A. Parke, and D. Gordon, “Is prostacyclin the major pro-inflammatory prostanoid in joint fluid?” Life Sciences, vol. 27, no. 7, pp. 603–608, 1980.

[84] S. L. Dorris and R. S. Peebles Jr., “PGI(2) as a regulator of inflammatory diseases,” Mediators of Inflammation, vol. 2012, Article ID 926968, 9 pages, 2012.

[85] K. R. Bley, A. Bhattacharya, D. V. Daniels et al., “RO1138452 and RO3244794: characterization of structurally distinct, potent and selective IP (prostacyclin) receptor antagonists,” British Journal of Pharmacology, vol. 147, no. 3, pp. 335–345, 2006.

[86] K. Watanabe, “Prostaglandin F synthase,” Prostaglandins and Other Lipid Mediators, vol. 68-69, pp. 401–407, 2002.

[87] Y. Sugimoto, K. Y. Hasumoto, T. Namba et al., “Cloning and expression of a cDNA for mouse prostaglandin F receptor,” The Journal of Biological Chemistry, vol. 269, no. 2, pp. 1356–1360, 1994.

[88] K. L. Pierce, H. Fujino, D. Srinivasan, and J. W. Regan, “Activation of FP prostanooid receptor isoforms leads to rho-mediated changes in cell morphology and in the cell cytoskeleton,” The Journal of Biological Chemistry, vol. 274, no. 50, pp. 35944–35949, 1999.

[89] K. Nakahata, H. Kinoshita, Y. Tokinaga et al., “Vasodilation mediated by inward rectifier K+ channels in cerebral microvessels of hypertensive and normotensive rats,” Anesthesia and Analgesia, vol. 102, no. 2, pp. 571–576, 2006.

[90] K. Takayama, K. I. Yuhki, K. Ono et al., “Thromboxane A2 and prostaglandin F2alpha mediate inflammatory tachycardia,” Nature Medicine, vol. 11, no. 5, pp. 562–566, 2005.

[91] C. L. Alexander, S. J. Miller, and S. R. Abel, “Prostaglandin analog treatment of glaucoma and ocular hypertension,” Annals of Pharmacotherapy, vol. 36, no. 3, pp. 504–511, 2002.

[92] Y. Sugimoto, A. Yamasaki, E. Segi et al., “Failure of parturition induced by cyclooxygenase in mice lacking the prostaglandin F2 receptor,” Science, vol. 277, no. 5326, pp. 681–683, 1997.

[93] M. D. Breyer and R. M. Breyer, “G protein–coupled prostanoiod receptors and the kidney,” Annual Review of Physiology, vol. 63, pp. 579–605, 2001.

[94] S. Basu, “Oxidative injury induced cyclooxygenase activation in experimental hepatotoxicity,” Biochemical and Biophysical Research Communications, vol. 254, no. 3, pp. 764–767, 1999.

[95] S. Basu and M. Eriksson, “Oxidative injury and survival during endotoxemia,” FEBS Letters, vol. 438, no. 3, pp. 159–160, 1998.

[96] S. Basu, M. Whiteman, D. L. Mattey, and B. Halliwell, “Raised levels of F2-isoprostanes and prostaglandin F2alpha in different rheumatic diseases,” Arthritis Research, vol. 6, no. 6, pp. 627–631, 2001.